HCR · Health Issues
340B drug discount program; drug pricing; importation of biopharmaceuticals; direct-to-consumer (DTC) advertising; transparency; international pharmaceutical supply chain; PBM reform; TRICARE Pharmacy Program (FY2026 National Defense Authorization Act (S.2296/H.R.3838/P.L.119-60); Pandemic and All-Hazards Preparedness Act (PAHPA) reauthorization; S.891, Bipartisan Health Care Act; S.527, Prescription Pricing for the People Act of 2025; S.1040, Drug Competition Enhancement Act; S.1041, Affordable Prescriptions for Patients Act; S.1097, Interagency Patent Coordination and Improvement Act of 2025; S.1095, Stop STALLING Act; S.1096, Preserve Access to Affordable Generics and Biosimilars Act; Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients.
Literal federal measure citations: S.2296, H.R.3838, S.891, S.527, S.1040, S.1041, S.1097, S.1095, S.1096
MMM · Medicare/Medicaid
General issues related to Medicare and Medicaid, including: Part D Medicare Program; Medicare Part B reimbursement; noninterference; CMMI Drug Pricing Demonstration Programs; drug pricing; Valued-Based Payments; H.R.1492/S.832, EPIC Act of 2025; Inflation Reduction Act of 2022 (P.L.117-169) implementation; H.R.1, One Big Beautiful Bill Act (P.L.119-21) implementation.
Literal federal measure citations: H.R.1492, S.832, H.R.1
CPT · Copyright/Patent/Trademark
Biopharmaceutical innovation and patent policy issues. Bayh-Dole march-in rights policy issues.
TRD · Trade (domestic/foreign)
Issues related to pharmaceutical IP, supply chain, and tariffs; Section 232 tariff investigation on branded pharmaceuticals. Issues related to foreign biotechnology companies (FY2026 National Defense Authorization Act (S.2296/H.R.3838/P.L.119-60).
Literal federal measure citations: S.2296, H.R.3838
